The Availability of MET Inhibitors for NSCLC

preview_player
Показать описание
Edward Garon, MD, discusses the FDA breakthrough therapy designation for tepotinib as a treatment for patients with metastatic NSCLC harboring METex14 skipping alterations and the new frontier in precision oncology.

  1. Targeted Oncology
  2. targeted oncology
  3. oncology
  4. cancer
Рекомендации по теме
The Availability of 0:03:35

The Availability of MET Inhibitors for NSCLC

Proposing the best 0:00:42

Proposing the best MET inhibitor to improve anti-PD-1 efficacy in HCC

Impact of MET 0:03:24

Impact of MET Inhibitors in MET Exon 14-Mutant NSCLC

Dr. Awad on 0:01:37

Dr. Awad on Acquired Resistance to MET Inhibitors in NSCLC

Efficacy of dual 0:01:41

Efficacy of dual EGFR and MET inhibition in NSCLC post EGFR TKI failure

Dr. Gregory Riely 0:00:45

Dr. Gregory Riely on Potential Treatment for Patients With MET Exon 14 Mutation

Phil Bonomi, MD, 0:00:41

Phil Bonomi, MD, offers opinion on whether MET inhibitors are effective in metastatic NSCLC

Dr. Manish Shah 0:01:06

Dr. Manish Shah on MET Inhibitors Not Improving PFS in MET-Positive GEC

New Research: Stage 0:07:13

New Research: Stage lV NSCLC - New Targets (MET) - ASCO 2019

Sym015 shows superior 0:01:36

Sym015 shows superior specificity compared to TKIs for NSCLC

What role will 0:00:32

What role will MET inhibitors have in managing papillary renal cancer?

MET as a 0:01:36

MET as a Clinical Target in Lung Cancer

METex14 SAs (MET 0:03:40

METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer

Emerging c-MET Inhibitors 0:04:58

Emerging c-MET Inhibitors in HCC

Lung Cancer research 0:02:13

Lung Cancer research presented by Dana-Farber at ASCO 2020

Dr Machaalani on 0:01:45

Dr Machaalani on Overcoming Acquired Resistance Through AXL and c-Met Inhibition in RCC

Combination strategies for 0:00:43

Combination strategies for lung cancer resistant to targeted therapies

Dr. Drilon on 0:01:10

Dr. Drilon on MET-Amplified Lung Cancer

The development of 0:03:25

The development of MET inhibitor by Jessica Spagnuolo

Blocking C-MET and 0:01:30

Blocking C-MET and BRAF pathways in melanoma to overcome resistance in mouse models

MET Inhibitor Rescues 0:03:39

MET Inhibitor Rescues Some Targeted Tx Failures in NSCLC - Medpage Today

Dr. Reckamp on 0:01:13

Dr. Reckamp on Pivotal Data in METex14-Altered NSCLC

HST-1011, an oral 0:00:40

HST-1011, an oral CBL-B inhibitor, alone and in combination with anti-PD1 in advanced solid tumors

Development of Novel 0:10:10

Development of Novel MET inhibitors by Jessa Na

visit shbcf.ru